205 related articles for article (PubMed ID: 26977270)
1. BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia.
Falchi L; Baron JM; Orlikowski CA; Ferrajoli A
Mediterr J Hematol Infect Dis; 2016; 8(1):e2016011. PubMed ID: 26977270
[TBL] [Abstract][Full Text] [Related]
2. [Chronic lymphocytic leukemia].
Aoki S
Rinsho Ketsueki; 2016 Mar; 57(3):238-48. PubMed ID: 27076234
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.
Puła A; Stawiski K; Braun M; Iskierka-Jażdżewska E; Robak T
Leuk Lymphoma; 2018 May; 59(5):1084-1094. PubMed ID: 28891366
[TBL] [Abstract][Full Text] [Related]
4. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
5. Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
von Tresckow J; Heyl N; Robrecht S; Giza A; Aldaoud A; Schlag R; Klausmann M; Linde H; Stein W; Schwarzer A; Fischer K; Cramer P; Eichhorst B; Hallek M; Fink AM
Ann Hematol; 2023 Nov; 102(11):3083-3090. PubMed ID: 37358640
[TBL] [Abstract][Full Text] [Related]
6. The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia.
Nair KS; Cheson B
Ther Adv Hematol; 2016 Apr; 7(2):69-84. PubMed ID: 27054023
[TBL] [Abstract][Full Text] [Related]
7. Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.
Arnason JE; Brown JR
Curr Oncol Rep; 2017 Sep; 19(9):61. PubMed ID: 28755313
[TBL] [Abstract][Full Text] [Related]
8. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
9. Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia.
Kakodkar P; More S; András K; Papakonstantinou N; Kelly S; Makrooni MA; Ortutay C; Szegezdi E
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664705
[TBL] [Abstract][Full Text] [Related]
10. A novel
Primo D; Scarfò L; Xochelli A; Mattsson M; Ranghetti P; Espinosa AB; Robles A; Gorrochategui J; Martínez-López J; de la Serna J; González M; Gil AC; Anguita E; Iraheta S; Munugalavadla V; Quéva C; Tannheimer S; Rosenquist R; Stamatopoulos K; Ballesteros J; Ghia P
Oncotarget; 2018 May; 9(40):26019-26031. PubMed ID: 29899839
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.
Bose P; Gandhi VV; Keating MJ
Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1381-1392. PubMed ID: 27686109
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia.
Maharaj K; Sahakian E; Pinilla-Ibarz J
Blood Adv; 2017 Sep; 1(21):1867-1875. PubMed ID: 29296833
[TBL] [Abstract][Full Text] [Related]
13. [Reaserch Advance on Inhibitor Targeting at the B-Cell Receptor Pathway in Chronic Lymphocytic Leukemia --Review].
Ji TT; Chen QN; Tao SD; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):708-712. PubMed ID: 32319422
[TBL] [Abstract][Full Text] [Related]
14. Management of chronic lymphocytic leukemia.
Stilgenbauer S; Furman RR; Zent CS
Am Soc Clin Oncol Educ Book; 2015; ():164-75. PubMed ID: 25993154
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib for treatment of B-cell malignancies.
Do B; Mace M; Rexwinkle A
Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
[TBL] [Abstract][Full Text] [Related]
16. New developments in the management of chronic lymphocytic leukemia: role of ofatumumab.
Laurenti L; Innocenti I; Autore F; Sica S; Efremov DG
Onco Targets Ther; 2016; 9():421-9. PubMed ID: 26855591
[TBL] [Abstract][Full Text] [Related]
17. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
18. [Chronic lymphocytic leukemia: pathophysiology and current therapy].
Takizawa J
Rinsho Ketsueki; 2017; 58(5):471-479. PubMed ID: 28592762
[TBL] [Abstract][Full Text] [Related]
19. Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.
Mauro FR; Caputo MD; Rosati S; Pepe S; De Benedittis D; De Luca ML; Foà R
Expert Rev Hematol; 2018 Aug; 11(8):601-611. PubMed ID: 29969322
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
